Analyst Consensus ?
ConsensusBuy29 ratings
Bullish1551.7%
Neutral1448.3%
Bearish00.0%
Revvity, Inc. · RVTY · FY2024 Q3 · Calendar Q4 2024
Revvity raises EPS outlook as China weakness weighs on growth
The quarter supports a mixed view of Revvity's growth trajectory: diagnostics, reagents, AI-enabled products, and cash generation provide support, but China's instrument weakness and the lower organic-growth outlook temper the near-term case.
Reported Before market openNYSEHealthcare
$16.84B market cap
100quality score
Earnings scorecard
Reported versus consensus
Reported EPS
$1.28
Consensus $1.13
EPS surprise
+13.3%
Reported versus consensus
Reported revenue
$641.7M
Consensus $679.6M
Revenue surprise
-5.6%
Reported versus consensus
Market reaction
prior-close to event-session close
Stock move
+3.1%
Event window
SPY move
-0.2%
Same window
Abnormal move
+3.3%
Stock minus SPY
Volume
3.2×
Versus trailing sessions
Subsequent drift
-7.9%
Up to 20 sessions
RVTYSPY benchmark
Ask FN2 about RVTY FY2024 Q3
Transcript, numbers and history already loaded
Why did RVTY rise 3.1% after beating EPS estimates in FY2024 Q3?What changed in RVTY's guidance and outlook in FY2024 Q3?Give me the bull and bear case for RVTY after FY2024 Q3 earnings.
Free account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
Management raised adjusted EPS guidance and highlighted strong cash generation, new AI-enabled offerings, and diagnostics initiatives. At the same time, it reduced the full-year organic revenue-growth outlook to 0-1% because of weaker instrument sales, particularly in China.
Guidance delta
EPS guidance was raised to $4.83-$4.87, while the full-year organic revenue growth outlook was reduced to 0-1%.
Key takeaways
- Management raised 2024 adjusted EPS guidance but lowered the organic revenue-growth outlook because of weaker instrument sales, especially in China.
- Q3 free cash flow was $135 million, with management targeting $550 million for the full year.
- Diagnostics, life-science reagents, AI-enabled products, and a planned TB automation launch were highlighted as growth avenues.
- The board approved a new $1 billion share-repurchase authorization.
Management priorities
- Support diagnostics and life-science reagent growth
- Expand AI-enabled products and diagnostics offerings
- Launch the TB automation platform
- Develop the BARDA-funded diagnostics platform
- Continue share repurchases and investment in growth projects
Follow RVTY with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEarnings History
Estimate
Beat
Miss
Match
Analyst 52W Price Targets
$150.94Current
$95Low
$124.13Average
$165High
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Oct 20, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| TD Cowen | Buy | Buy | Maintain | Oct 13, 2026 |
| Barclays | Equal Weight | Equal Weight | Maintain | Oct 7, 2026 |
| Keybanc | Overweight | Overweight | Maintain | Sep 4, 2026 |
| Evercore ISI Group | Outperform | Outperform | Maintain | Aug 5, 2026 |
| Stifel | Hold | Hold | Maintain | May 6, 2026 |
| JP Morgan | Neutral | Neutral | Maintain | May 6, 2026 |
| Baird | Outperform | Outperform | Maintain | May 4, 2026 |
| Goldman Sachs | Neutral | Neutral | Maintain | Apr 14, 2026 |
| Wells Fargo | Equal Weight | Equal Weight | Maintain | Feb 3, 2026 |
| Jefferies | Hold | Hold | Maintain | Feb 3, 2026 |
| B of A Securities | Buy | Buy | Maintain | Sep 22, 2025 |
| Raymond James | Outperform | Outperform | Maintain | Jul 29, 2025 |
| UBS | Buy | Neutral | Upgrade | May 1, 2025 |
| Bernstein | Outperform | Outperform | Maintain | Nov 5, 2024 |
| Leerink Partners | Outperform | Outperform | Maintain | Oct 17, 2024 |
| Citigroup | Buy | Buy | Maintain | Jul 30, 2024 |
| Cowen & Co. | Outperform | Market Perform | Upgrade | Dec 5, 2022 |
| Credit Suisse | Neutral | Neutral | Maintain | Nov 13, 2022 |
| Needham | Buy | Buy | Maintain | Nov 8, 2020 |
| CFRA | Hold | Hold | Maintain | May 5, 2020 |
| Piper Sandler | Neutral | Overweight | Downgrade | Oct 30, 2019 |
| Morgan Stanley | Overweight | Overweight | Maintain | Jan 2, 2019 |
| Janney Montgomery Scott | Neutral | Buy | Downgrade | Nov 1, 2018 |
| Deutsche Bank | Hold | Hold | Maintain | Apr 8, 2018 |
| Mizuho | Neutral | Buy | Downgrade | Aug 4, 2016 |
| Wedbush | Neutral | Outperform | Downgrade | Dec 2, 2015 |
| ISI Group | Neutral | Buy | Downgrade | Apr 8, 2014 |
| Macquarie | Outperform | Neutral | Upgrade | Dec 9, 2013 |
| CLSA | Buy | Outperform | Maintain | Jan 16, 2013 |
Named analyst price targets
Upside is calculated against the persisted current price $150.94. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| Barclays | Analyst unavailable | $160 | $153.3 | +6.0% | Oct 7, 2026 |
| UBS | Analyst unavailable | $140 | $127.08 | -7.2% | Sep 9, 2026 |
| KeyBanc | Analyst unavailable | $165 | $130.63 | +9.3% | Sep 4, 2026 |
| RBC Capital | Dan Leonard | $135 | $128.67 | -10.6% | Sep 1, 2026 |
| Evercore ISI | Vijay Kumar | $125 | $111.66 | -17.2% | Jul 6, 2026 |
| Bernstein | Analyst unavailable | $115 | $113.53 | -23.8% | Jun 26, 2026 |
| Stifel Nicolaus | Analyst unavailable | $100 | $92.3 | -33.7% | May 6, 2026 |
| Robert W. Baird | Catherine Ramsey Schulte | $117 | $92.3 | -22.5% | May 6, 2026 |
| Robert W. Baird | Analyst unavailable | $125 | $86.68 | -17.2% | May 4, 2026 |
| Barclays | Luke Sergott | $95 | $92.64 | -37.1% | Apr 14, 2026 |
| Robert W. Baird | Catherine Ramsey Schulte | $129 | $103.89 | -14.5% | Feb 3, 2026 |
| Cowen & Co. | Analyst unavailable | $124 | $106.97 | -17.8% | Feb 3, 2026 |
| Evercore ISI | Analyst unavailable | $118 | $107.09 | -21.8% | Feb 3, 2026 |
| Barclays | Analyst unavailable | $118 | $107.09 | -21.8% | Feb 3, 2026 |
| Jefferies | Analyst unavailable | $105 | $107.05 | -30.4% | Feb 2, 2026 |
| Wells Fargo | Brandon Couillard | $107 | $100.46 | -29.1% | Dec 15, 2025 |
| Barclays | Luke Sergott | $115 | $100.46 | -23.8% | Dec 15, 2025 |
| Goldman Sachs | Evie Koslosky | $105 | $99.79 | -30.4% | Dec 9, 2025 |
| Robert W. Baird | Analyst unavailable | $123 | $97.74 | -18.5% | Oct 28, 2025 |
| Barclays | Analyst unavailable | $105 | $97.16 | -30.4% | Oct 28, 2025 |
| Evercore ISI | Analyst unavailable | $108 | $95.88 | -28.4% | Oct 27, 2025 |
| Robert W. Baird | Catherine Ramsey Schulte | $122 | $98.64 | -19.2% | Oct 24, 2025 |
| Barclays | Analyst unavailable | $100 | $91.76 | -33.7% | Oct 2, 2025 |
| Raymond James | Andrew Cooper | $140 | $116.6 | -7.2% | Jan 21, 2025 |
| Bernstein | Eve Burstein | $130 | $113.88 | -13.9% | Jan 10, 2025 |
| KeyBanc | Paul Knight | $132 | $124.82 | -12.5% | Nov 4, 2024 |
| Barclays | Luke Sergott | $140 | $122.91 | -7.2% | Oct 15, 2024 |
| Bank of America Securities | Derik de Bruin | $127 | $125.59 | -15.9% | Jul 30, 2024 |
| Jefferies | Tycho Peterson | $125 | $125.29 | -17.2% | Jul 29, 2024 |
| Stifel Nicolaus | Daniel Arias | $110 | $120.16 | -27.1% | Jul 29, 2024 |
| Citigroup | Patrick Donnelly | $135 | $120.16 | -10.6% | Jul 29, 2024 |
| Evercore ISI | Vijay Kumar | $126 | $120.16 | -16.5% | Jul 29, 2024 |
| UBS | Dan Leonard | $120 | $105.02 | -20.5% | Apr 29, 2024 |
Track every rating change on RVTY the moment it posts. Free to start.
Start freeCompany context
Snapshot as of publicationRevvity, Inc., founded in 1937 and based in Waltham, Massachusetts, is a global enterprise that develops and delivers a wide array of products, services, and solutions. The company, which changed its name from PerkinElmer, Inc. in April 2023, caters to the diagnostics, life sciences, and applied services sectors worldwide. Its Discovery & Analytical Solutions division provides advanced instrumentation, reagents, informatics, software, subscriptions, and sophisticated detection and imaging technologies. These resources are designed to enable scientists to achieve significant breakthroughs in life sciences research. This segment also offers contract research and specialized laboratory services. Furthermore, it supplies analytical tools and services for assessing environmental health, including air, water, and soil, and delivers solutions to agricultural and food producers.…
Historical context
All RVTY earningsLatest beats and misses
Who reports nextBeat on EPS
Missed on EPS
Get the RVTY recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
- FN2 earnings calendar · 2024-11-10T18:38:36.707185+00:00
- Polygon adjusted daily market bars · 2026-10-20T01:50:45.352014+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-10-20T01:50:45.349224+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-10-20. For educational purposes only; not investment advice.